News

The BCMA-CD3 bispecific antibody outperformed daratumumab plus pomalidomide and dexamethasone in double-class exposed patients.

FDA designates TERN-701 as breakthrough therapy for heavily pretreated Ph+ CP-CML, as allosteric BCR-ABL inhibitor shows rapid deep molecular responses and tolerable safety.

The COMPANION-002 trial in biliary tract cancer allowed crossover to the tovecimig arm which likely confounded overall survival data.

During a Case-Based Roundtable event, Thomas LeBlanc, MD, discussed risk stratification and the latest data regarding luspatercept and imetelstat for lower-risk MDS.

Study finds Gemini and GPT catch oncology chart errors, improving documentation accuracy and patient safety with clinician oversight.

The DNA ImmunoBody therapy improved efficacy when added to ipilimumab and nivolumab, with a registrational phase 3 trial expected to begin later this year.

FDA accepted the NDA for zipalertinib to treat previously treated metastatic NSCLC with EGFR exon 20 insertion mutations. Target action date: 2/27/27.

NCCN now recommends taletrectinib for ROS1+ NSCLC with brain metastases, citing high intracranial response rates in TKI-naive and pretreated patient cohorts.

The FDA has has granted a priority review to zanidatamab-based regimens for the first-line treatment of patients with gastroesophageal adenocarcinoma.

Premal Thaker, MD, MS, discusses IMNN-001 boosts overall survival in advanced ovarian cancer, with bigger gains alongside PARP inhibitors, as phase 3 OVATION 3 ramps up.

Advanced genomic profiling in community oncology uncovers actionable cancer mutations and trial options—yet insurance denials still block access.

During a live event, Caitlin Costello, MD, discussed the AQUILA trial and its potential impact on treatment for high-risk smoldering myeloma.

With long-term follow-up, HLA-A*02:01–positive patients with metastatic uveal melanoma maintained survival benefit with the bispecific agent vs investigator's choice.

Explore real-world extensive-stage SCLC care, with frontline chemoimmunotherapy, steep therapy attrition, NCCN updates, and evidence favoring 4 chemotherapy cycles.

Odronextamab delivers higher responses and longer control in later-line follicular lymphoma versus real-world therapies, new analysis reports.

As regulators examine the on-body injector used with isatuximab in multiple myeloma, Sikander Ailawadhi, MD, provides commentary on frequently asked questions.

The monoclonal antibody LYT-200 demonstrated promising clinical activity and a favorable safety profile in patients with high-risk myelodysplastic syndrome.

The target date for the FDA's decision on isatuximab via on-body injector is now July 23, 2026.

During a live event, participants discuss barriers to access and bridging strategies for tumor-infiltrating lymphocytes in melanoma.

The treatment landscape for high- and low-risk polycythemia vera is shifting with large scale studies such REVEAL and Low-PV changing practice.

The phase 3 LITESPARK-012 trial failed to meet primary end points of PFS/OS for adding belzutifan or quavonlimab to the standard pembro/lenvatinib doublet.

BBO-11818 has received FDA fast track designation for KRAS-mutant pancreatic cancer, with early phase 1 data showing antitumor activity.

UK trial data show TP53 and unmutated IGHV outperform copy-number complexity for CLL prognosis, guiding smarter molecular risk stratification.

mRNA-4359 demonstrated high response rates and antigen-specific T-cell activation in a small cohort of previously untreated patients.

Gut microbiome bacteria are linked to risk of recurrence after treatment with immunotherapy for resectable melanoma.

A brain-penetrant pan-RAF/MEK molecular glue demonstrated a 38% response rate in a heavily pretreated melanoma population that currently has no approved targeted therapies.

Phase 1 trial of JANX014, a PSMA-targeted T-cell engager, begins in mCRPC, building on prior safety data to expand treatment strategies.

The FDA has granted a priority review to the supplemental biologics license application for enfortumab vedotin/pembrolizumab to all patients with MIBC regardless of cisplatin eligibility.